Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golcadomide and Nivolumab in Refractory NHL After CAR-T Therapy
NCT06767956Phase 2Withdrawn
- Sponsor
- University of Pittsburgh
- Start
- Jun 2025
- Primary completion
- Apr 2027
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of golcadomide in non-Hodgkin lymphoma (NHL), sponsored by University of Pittsburgh. Primary endpoints: Maximum tolerated dose / Recommended Phase 2 dose at 56 days and Overall Response Rate per Lugano Response Evaluation at 36 months. Planned start Jun 2025; status: withdrawn.
02
Drugs
golcadomide
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT06767956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06767956.